Hans Lennart Rudolf Wigzell sold $1.3M of SRPT
director at Sarepta Therapeutics, Inc.. 10,500 shares at an average of $124.84, traded Dec 12, 2024, filed Dec 16, 2024.
Score components
- +15RoleDirector
- +25Trade size$1.3M at market
- +10Share of holdings soldSold 31% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-136847, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2024 | MOption exercise Common Stock | +10,500 | $13.71 | $144k | 33,340 | Dec 16, 2024 |
| Dec 12, 2024 | SOpen-market sale Common Stock | -10,500 | $124.84 | $1.3M | 22,840 | Dec 16, 2024 |
| Dec 12, 2024 | MOption exercise Stock Options (right to buy)derivative | -10,500 | $0.00 | $0 | 0 | Dec 16, 2024 |
Related signals
Other insiders at Sarepta Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $205k 1,636 shares | -22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.